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Summary
 
The human immunodeficiency virus type 1 (HIV-1) 
 
vpu
 
 gene encodes a small integral mem-
brane phosphoprotein with two established functions: degradation of the viral coreceptor CD4
in the endoplasmic reticulum (ER) and augmentation of virus particle release from the plasma
membrane of HIV-1–infected cells. We show here that Vpu is also largely responsible for the
previously observed decrease in the expression of major histocompatibility complex (MHC)
class I molecules on the surface of HIV-1–infected cells. Cells infected with HIV-1 isolates that
fail to express Vpu, or that express genetically modified forms of Vpu that no longer induce CD4
degradation, exhibit little downregulation of MHC class I molecules. The effect of Vpu on class
I biogenesis was analyzed in more detail using a Vpu-expressing recombinant vaccinia virus (VV).
VV-expressed Vpu induces the rapid loss of newly synthesized endogenous or VV-expressed
class I heavy chains in the ER, detectable either biochemically or by reduced cell surface ex-
pression. This effect is of similar rapidity and magnitude as the VV-expressed Vpu-induced
degradation of CD4. Vpu had no discernible effects on cell surface expression of VV-expressed
mouse CD54, demonstrating the selectivity of its effects on CD4 and class I heavy chains. VV-
expressed Vpu does not detectably affect class I molecules that have been exported from the
ER. The detrimental effects of Vpu on class I molecules could be distinguished from those
caused by VV-expressed herpes virus protein ICP47, which acts by decreasing the supply of
cytosolic peptides to class I molecules, indicating that Vpu functions in a distinct manner from
ICP47. Based on these findings, we propose that Vpu-induced downregulation of class I mole-
cules may be an important factor in the evolutionary selection of the HIV-1–specific 
 
vpu
 
 gene
by contributing to the inability of CD8
 
1
 
 T cells to eradicate HIV-1 from infected individuals.
 
C
 
D8
 
1
 
 T cells (T
 
CD8
 
1
 
)
 
1
 
 play a critical role in immune
responses to many viruses. T
 
CD8
 
1
 
 recognize MHC
class I (MHC-I) molecules bearing viral peptides on the
surface of virus-infected cells (1, 2). MHC-I molecules
consist of three noncovalently associated subunits: an inte-
gral membrane glycoprotein of 44 kD (H chain), a small
soluble protein (
 
b
 
2
 
-microglobulin [
 
b
 
2
 
m]), and an oligopep-
tide, usually 8–10 residues in length (3). Peptides are de-
rived from a cytosolic pool of viral and cellular protein pre-
cursors (4, 5). Cytosolic peptides are transported into the
endoplasmic reticulum (ER) by TAP (transporter-associ-
ated with antigen presentation [6–8]). TAP-transported
peptides induce the release of newly synthesized H chain–
 
b
 
2
 
m tethered to TAP. The assembled tripartite complex
reaches the cell surface via the standard exocytic pathway.
A number of viruses have evolved strategies to downreg-
ulate antigen presentation by MHC-I molecules (9, 10).
Viral proteins may inhibit MHC-I gene promoter activity
(11), retain class I molecules in the ER (12), destroy H
chains in the ER (13, 14), dislocate nascent H chains into
the proteasome pathway (15), or block the function of
TAP (16–18). A decrease in class I expression on the cell
surface occurs after infection with HIV type 1 (HIV-1; 19–
21), and has been suggested as a reason for the inability of
T
 
CD8
 
1
 
 to eliminate the infection in vivo (22).
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2
 
m, 
 
b
 
2
 
-microglobulin; CHAPS, 3-(3-
cholamidopropyl)diethylammonio-1 propane sulfonate; ER, endoplasmic
reticulum; pAbs-ex8, exon 8–specific polyclonal antibodies; rVV, recom-
binant VV; SIV, simian immunodeficiency virus; TAP, transporter associ-
ated with antigen presentation; T
 
CD8
 
1
 
, CD8
 
1
 
 T cells; VV, vaccinia virus.
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The mechanism underlying this phenomenon is uncer-
tain. Transcriptional analyses (11,19) provided evidence
that this effect is due to a decrease in the transcription of
genes encoding class I H chains. Howcraft et al. (11) used a
swine MHC-I gene to demonstrate that the HIV transacti-
vator Tat specifically decreases MHC-I gene promoter ac-
tivity. However, Matsui et al. (23) found that Tat affects
neither the expression, stability, nor transport of H chains.
Consistent with these findings, we found that alterations in
H chain–encoding transcripts do not account for decreases
in MHC-I expression, and suggested that HIV affects class I
expression at a posttranscriptional level (20, 21).
In the present communication, we examine the role of
the HIV-1–specific Vpu protein in the downregulation of
MHC-I molecules. Vpu is an 81-residue oligomeric type
1–anchored membrane protein that consists of a hydropho-
bic membrane anchor and a polar phosphorylated cytoplas-
mic tail (24–29). Among primate lentiviruses, Vpu is appar-
ently encoded exclusively by HIV-1 and its close relatives
(30). Like other so-called accessory genes of HIV-1, Vpu is
not essential for virus replication in vitro (24, 25, 31, 32).
However, Vpu consistently increases viral replication in
T cell lines (24–26, 31, 32) and primary lymphocyte and
macrophage cultures (33). It is possible that Vpu contrib-
utes to the increased virulence of HIV-1 relative to HIV-2
(34, 35). This hypothesis is supported by observations that
Vpu enhances virus load and spread of infection in cyno-
molgus monkeys (36) and in SCID mice reconstituted with
human immune cells (37).
Two distinct biological activities, which could contrib-
ute to the pathogenic potential of HIV-1, are attributed to
Vpu: augmentation of virus particle release from the plasma
membrane (24, 25, 30–33) and induction of proteolytic
degradation of newly synthesized virus receptor CD4 in the
ER (38, 39). One direct consequence of the Vpu-mediated
CD4 proteolysis is to facilitate transport and processing of
the envelope glycoprotein gp160 (38), which would other-
wise be trapped in the ER because of the formation of sta-
ble complexes with CD4 (40). Therefore, in HIV-1–infected
cells, the two separable function of Vpu ensure that suffi-
cient quantities of Env proteins reach the cell surface for
incorporation into an increased number of budding virions.
In this report, we demonstrate that Vpu exhibits another
important biological activity that could contribute to the
increased pathogenicity of HIV-1 in comparison to HIV-2
(34, 35): Vpu decreases the cell surface expression of
MHC-I molecules by interfering with an early step in class
I biogenesis.
 
Materials and Methods
 
Cell Culture and Infection.
 
T
 
CD8
 
1
 
 cells were removed from
buffy-coat cells of an HIV-negative HLA A-2,3–positive donor
by magnetic beads coupled with an mAb specific for human CD8
(Dianova GmbH, Hamburg, Germany). The remaining CD8
 
2
 
cells were stimulated with PHA (2 
 
m
 
g/ml) in the presence of 100
U/ml recombinant IL-2 for 2 d. 10
 
6
 
 stimulated cells were in-
fected with 5 
 
3
 
 10
 
4
 
 tissue culture infectious doses, each of
HIV-1
 
IIIB
 
 (41, 42), HIV-2
 
D205
 
, simian immunodeficiency virus
(SIV)
 
mac
 
, or HIV-1
 
NL4-3
 
 (43), and the isogeneic 
 
vpu
 
 mutants
HIVNL-U
 
35
 
 (24) and HIVNL4-3/U
 
2/6
 
 (44). A3.01 cells (45)
were cultivated in RPMI 1640/FCS. Routinely, 2 
 
3
 
 10
 
6
 
 reverse
transcriptase units were used to infect 10
 
7
 
 A3.01 cells. After 15 h
of absorption, cells were maintained at 10
 
6
 
 cells/ml as described
previously (33, 46). Analyses of MHC-I expression was performed
approximately at peak virus production, usually at day 12 after infec-
tion.
 
Flow Cytometry.
 
4 d after infection, aliquots from controls
and infected PBL cultures were washed and incubated for 30 min
on ice with mAb IOT 2 (Dianova GmbH). Cells were washed,
incubated with FITC-conjugated goat anti–mouse Ig for 30 min
on ice, washed, fixed in 3.5% formaldehyde, and analyzed on a
cytofluorograph. To monitor infections, cells were fixed with
3.5% formaldehyde for 30 min at room temperature, washed, and
treated for 20 min at room temperature with 0.25% Triton X-100
in PBS. Cells were then washed, incubated for 30 min at room
temperature in 10% heat-inactivated sheep serum, washed, and
incubated for 1 h at room temperature with purified polyclonal
sheep antibody specific for HIV-1 p24
 
gag
 
 (Biochrom, Berlin, Ger-
many). After extensive washing, cells were incubated with a 1:50
dilution of an FITC-conjugated polyclonal goat anti–sheep anti-
body and analyzed by flow cytometry. For detection of p27
 
gag
 
,
the FITC-conjugated mAb 2F12 (Biochrom) was used.
HeLa cells were infected for various times as indicated in the
text with recombinant vaccinia viruses (rVVs) and incubated on
ice for 30 min with FITC-conjugated antibodies specific for HLA
class I molecules, W6/32 (Accurate Chem. & Sci. Corp., West-
bury, NY), human 
 
b
 
2
 
m (The Binding Site, Inc., San Diego, CA),
mouse CD54 (PharMingen, San Diego, CA), mouse H-2 K
 
b
 
, or
human transferrin receptor (Becton Dickinson, San Jose, CA).
Antibodies specific for mouse H-2 K
 
b
 
 were purified from the hy-
bridoma cell line Y3 (American Type Culture Collection HB
176) and FITC-conjugated using standard procedures. After stain-
ing, HeLa cells were washed and resuspended in PBS supple-
mented with 10 
 
m
 
g/ml ethidium homodimer and analyzed by
flow cytometry. Nonviable cells were excluded from analysis.
 
rVVs.
 
rVVs were generated and propagated as described (47).
Vpu-expressing rVVs were produced by cloning either wild-type
Vpu from HIV-1
 
NL4-3
 
 (VV-Vpu; 43) or the mutant vpuDEL-1
(VV-U
 
DEL1
 
; 31) behind the early/late VV p7.5 promoter. In
brief, a 290-bp AflIII-KpnI fragment of the plasmid pSP-9 (24) or
a 242-bp AflIII–KpnI fragment of the plasmid pSP-9/U
 
DEL1
 
 (46)
were cloned into the NcoI–KpnI sites of plasmid pSC11 (48)
yielding plasmids pSCVpu and pSC-U
 
DEL1
 
, respectively. VV-ICP47
(49), VV-K
 
d
 
 (50), VV-K
 
b
 
 (50), and vCB-3 (51) have been de-
scribed. VV–intracellular adhesion molecule (ICAM) expressing
mouse CD54 was created as described (47) by inserting cDNA (52)
behind the early/late VV p7.5 promoter into plasmid pSC11 (48).
 
Pulse Chase Metabolic Labeling.
 
At day 4, p.i. aliquots of 10
 
7
 
PBL were labeled with [
 
35
 
S]methionine (2 mCi/ml) for 45 min,
chased for the times indicated in the absence of radiolabeled me-
thionine, and lysed in 90 
 
m
 
l of 3-(3-cholamidopropyl)diethylammo-
nio-1 propanesulfonate (CHAPS) buffer (50 mM Tris, pH 8.0, 5
mM EDTA, 100 mM NaCl, 0.5% CHAPS) 
 
1
 
 15 
 
m
 
l CHAPS/deoxy-
cholate buffer (CHAPS buffer with 2% deoxycholate). For the
immunocollection of MHC-I molecules, lysates were precleared
with mouse IgG (1.5 h, 4
 
8
 
C) coupled to protein A–Sepharose fol-
lowed by specific immunocollection with HLA-specific mAb IOT2
(2 h, 4
 
8
 
C) coupled to protein A–Sepharose. Immunocollected
proteins were separated in a 10% SDS-PAGE and analyzed by
quantitative fluorography. HeLa cells infected at rVVs with 3–5 
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PFU/cell were starved for 20 min in methionine-free DMEM
and labeled for up to 15 min with [
 
35
 
S]methionine (2 mCi/ml).
Cells were washed, chased in DMEM containing 1 mg/ml
 
l
 
-methionine, and lysed in CHAPS/deoxycholate buffer. Cell ly-
sates were precleared by incubation at 4
 
8
 
C for 1 h with Gamma-
Bind G–Sepharose preadsorbed with 20 
 
m
 
g of preimmune rabbit
IgG, and incubated for 2 h with protein G–Sepharose preloaded
with one of the following antibodies: mAb W6/32 (Harlan Sprague
Dawley Inc., Indianapolis, IN), mAb SK81075 (Olympus Corp.,
Lake Success, NY), antihuman 
 
b
 
2
 
m serum from rabbit (Dakopatts,
Copenhagen, Denmark), mAb TW2.3 specific for vaccinia pro-
teins E3L/E3L
 
*
 
 (53), anti-Vpu sera from sheep (28) or rabbit
(27), mAb 215 directed against conformed H chain K
 
d
 
 (54), poly-
clonal rabbit antibodies directed against exon 8 of H-2 K locus H
chains (pAbs-ex8; reference 54), or anti-CD4 serum from rabbit
(55). Immunoprecipitated proteins were separated in 10% or
12.5% acryl aide gels. Radioactive bands were visualized in fixed
gels by fluorography and quantitated using a PhosphorImager.
 
Results
 
Effect of Vpu Expression on HIV-1–mediated Downregulation
of Class I Molecules.
 
We initially analyzed the potential
contribution of Vpu to MHC class I cell surface downregula-
tion by comparing the effects of infecting PHA/IL-2–acti-
vated, T
 
CD8
 
1
 
-depleted PBL with Vpu expressing HIV-1
 
IIIB
 
or the non-Vpu expressing viruses HIV-2
 
D205
 
, or SIV
 
mac
 
 (Fig.
1 
 
A
 
). Surface expression of class I molecules was deter-
mined by cytofluorographic analysis of cells indirectly stained
using a mAb specific for native, peptide-bearing class I
molecules. As previously reported (19, 20), HIV-1 infec-
tion resulted in an 
 
z
 
10-fold decrease in the class I signal of
a subpopulation of cells (Fig. 1 
 
A d
 
). This subpopulation
correlates numerically with the number of cells expressing
p24
 
gag
 
, and double fluorescence confirmed that class I was
selectively decreased in p24
 
gag
 
-expressing cells (not shown).
By contrast, infection with SIV or HIV-2 (Fig. 1 
 
A
 
, 
 
b
 
 and
 
c
 
) did not decrease class I expression to levels observed in
HIV-1
 
IIIB
 
–infected cells despite the fact that a comparable
percentage of cells expressed viral p24
 
gag
 
 antigens at similar
levels (Fig. 1 
 
A
 
, 
 
f–h
 
).
To specifically test the effect of Vpu on cell-surface class I
molecule expression in the context of HIV infection, we
used the molecular clone HIV-1
 
NL4-3
 
 (43) encoding either
functionally characterized wild-type or mutant Vpus (24,
25, 31, 38, 39). T
 
CD8
 
1
 
-depleted, IL-2/PHA-activated PBL
were infected with either wild-type HIVNL4-3 (43) or
one of two isogeneic mutant viruses. The first (HIVNL-U
 
35
 
)
encodes a 35 amino acid inactive Vpu protein with a
COOH-terminal truncation (24). The second (HIVNL4-
3/U
 
2/6
 
) encodes a full-length mutant, Vpu
 
2/6
 
, that cannot
be phosphorylated due to exchanging Asn for phosphoac-
ceptor Ser
 
52
 
 and Ser
 
56
 
 residues (29). Vpu
 
2/6
 
 has lost the ca-
pacity to induce CD4 degradation, but maintains the ability
to enhance virus secretion (44). Vpu
 
2/6
 
 exhibits similar struc-
ture, stability, oligomerization, membrane integration, and
subcellular localization as wild-type Vpu (46, 56).
Parallel cultures of PBL were infected with equal infec-
tious doses of the three viruses, and cell surface expression of
MHC-I molecules was analyzed 4 d after infection using a
mAb that recognizes conformed class I molecules. Down-
regulation of surface class I molecules observed in the pres-
ence of wild-type Vpu (Fig. 1 
 
B
 
, 
 
b
 
) was greatly compro-
mised by either of the alterations in Vpu (Fig. 1 
 
B
 
, 
 
c
 
 and 
 
d
 
).
As above, the biphasic pattern of the histograms observed
in the presence of Vpu reflects heterogeneity in HIV infection
of the PBL cultures, as clearly revealed by cytofluoro-
graphic analysis of p24
 
gag
 
 expression (Fig. 1 
 
B
 
, 
 
f–h
 
). Impor-
tantly, this demonstrated that there was no significant dif-
ference in either the number of p24gag-expressing cells or
the amount of p24gag expressed by cells infected with the
different clones. Thus, the inability of the Vpu mutants to
decrease class I expression cannot be trivially attributed to
impairment of viral replication and a concomitant decrease
in the expression of other viral gene products. The residual
slight decrease in class I expression exhibited by the Vpu
mutants (Fig. 1 B, c and d) is consistent with recent reports
that the HIV-1 accessory protein Nef induces endocytosis
of cell surface MHC-I (57).
Figure 1. (A) Cell surface expression of MHC-I molecules is downreg-
ulated in TCD81-depleted and PHA/IL-2–activated PBL infected with
HIV-1, but not in PBL infected with HIV-2 or SIV. Uninfected control
(a); PBL infected with HIV-2D205 (b); SIVmac (c); HIV-1BH10 (d); intracel-
lular staining for viral core proteins p24/p27gag (e–h). The thin curves to
the left in each histogram represent negative controls. (B) Downregula-
tion of MHC-I expression on HIV-1 PBL depends on the expression of
biologically active Vpu protein. Uninfected controls (a, e, and i); TCD81-
depleted and PHA/IL-2–activated PBL infected with wild-type
HIVNL4-3 (b, f, and j), the vpu2 mutant HIVNL-U35 (c, g, and k), and
HIVNL4-3/U2/6 encoding nonphosphorylated Vpu2/6 (d, h, and l). The
left curves in a, e, and i represent negative controls. Cells were stained
with either conformation-specific mAb I0T2 (a–d). Virus expression was
controlled by intracellular staining for p24gag (e–f).1298 HIV-1 Vpu Interferes with MHC Class I Biosynthesis
Biochemical Characterization of Effects of HIV-1–encoded
Vpu on Class I Biogenesis.  To further characterize the ef-
fect of Vpu on the expression of MHC-I molecules, PHA/
IL-2–activated, TCD81-depleted PBL from two donors were
infected for 4 d with HIVNL4-3 or isogenic vpu mutants,
and class I biogenesis was biochemically characterized (Fig.
2). After 45 min of radiolabeling with [35S]methionine and
chasing for various times at 378C, class I molecules reactive
with a mAb specific for conformed class I molecules were
collected, separated by SDS-PAGE, and quantitated. Cells
from either donor infected with wild-type virus demon-
strated a 30–40% reduction in the amount of class I mole-
cules recovered at the initiation of the chase, compared to
uninfected or vpu-deficient cultures (Fig. 2, B and C). Ad-
ditionally, an augmented decay of class I H chains was de-
tectable in the presence of wild-type Vpu after a 4-h chase
period (Fig. 2 A, 2) relative to either uninfected cells (Fig.
2  A,  1), cells infected with the Vpu-deficient mutant
HIVNL-U35 (Fig. 2 A, 3), or the Vpu phosphorylation
mutant HIVNL4-3/U2/6 (Fig. 2 C). Note that the effects
of Vpu on class I biosynthesis are underestimated in these
experiments because not all cells are infected in each cul-
ture (Fig. 1 B, f–h). Consistent with the Vpu-dependent ef-
fects in PBL (Fig. 2), class I molecules were also affected in
a Vpu-dependent manner in HIV-1–infected CD41 T cell
line A3.01 (not shown). Neither the amount of b2m recov-
ered from cell lysates nor its secretion into the culture su-
pernatant was altered by Vpu in HIV-1–infected PBL or
T cells (not shown), indicating that Vpu does not prevent
class I assembly by reducing b2m to limiting levels. Rather,
we conclude that the Vpu-dependent downregulation of
class I cell surface expression in cells infected with wild-type
HIV-1 largely reflects Vpu-mediated instability of MHC-I
molecules due to their improper assembly or enhanced
degradation.
Effects of rVV-expressed Vpu on Endogenous Class I Biogene-
sis. Several characteristics of HIV make it less than opti-
mal as a means of characterizing the effect of Vpu on class I
molecules. First, Vpu enhances the release of HIV from the
plasma membrane of infected cells (24, 25, 31–33). Since
HIV particles can contain large amounts of class I mole-
cules (58), this was a possible confounding factor in the ob-
served effect of Vpu on recovery of class I molecules (Fig.
2). Second, since HIV only infects a subset of cells, the ef-
fects of Vpu are obscured by processes unaffected in unin-
fected cells. To circumvent these problems, we produced
VV-Vpu. As a control for the possible effects of Vpu
mRNA, we also produced a rVV, VV-UDEL1, expressing
mRNA from the gene from the natural vpu mutant vpu-
DEL-1 (31) that carries a 48-bp deletion within the Vpu
transmembrane domain, resulting in the production of a
15-residue protein unrelated in sequence to Vpu (31).
Using a Vpu-specific antiserum, a protein with the pre-
dicted mobility of Vpu in SDS-PAGE was recovered from
HeLa cells infected with VV-Vpu (Fig. 3 A), but not with
VV-UDEL1 or from the uninfected culture. The stability of
Vpu expressed by VV-Vpu was comparable to the half life
of Vpu previously reported for HIV-1–infected or –trans-
fected human cell lines (25, 44, 46). To characterize the bi-
ological activity of Vpu in VV-infected cells, we examined
its effects on CD4 biogenesis. Mouse L929 cells were co-
infected with VV-Vpu and vCB-3 (expressing wild-type
human CD4; reference 51), radiolabeled for 7 min with
[35S]methionine, and then chased at 378C for up to 240
min (Fig. 3 B). Detergent extracts were immunoprecipi-
tated with an anti-CD4 antiserum, and analyzed by SDS-
Figure 2. Vpu compromises generation of MHC class I complexes in HIV-1 infected PBL. (A) Pulse/chase analysis of MHC-I molecules in TCD81-
depleted and PHA/IL-2–activated PBL infected with HIVNL4-3 (wild type, 1Vpu), or the mutant HIVNL-U35 (2Vpu); uninfected control (mock).
MHC class I complexes were immunoprecipitated with mAb W6/32, separated in a 10% acryl aide gel, and analyzed by fluorography. Only parts of the
fluorograms demonstrating H chain–specific bands in the range of 43 kD are shown. (B) Relative amounts of H chain proteins seen in (A) were quanti-
tated by means of an image analyzer and blotted against the time of the chase period (pu, nonstandardized arbitrary PhosphoImager units). (C) TCD81-
depleted and PHA/IL-2–activated PBL isolated from another donor were infected with HIVNL4-3 (1Vpu), HIVNL-U35 (2Vpu), or HIVNL4-3/U2/6
expressing a nonphosphorylated mutant (1Vpu2/6). Pulse/chase experiment, immunocollection, and SDS-PAGE analysis (not shown) were performed as
described for Fig. 2, A and B. Relative amounts of H chains were quantitated with a PhosphorImager and plotted in arbitrary units (pu) against the time
of the chase period.1299 Kerkau et al.
PAGE (Fig. 3 B, inset). The kinetics of CD4 decay were
determined by calculating the levels of CD4 present at dif-
ferent times relative to the levels of CD4 present at the end
of the pulse (0 min), which was defined as 100% (Fig. 3 B).
In the presence of rVV expressed Vpu, the half-life of CD4
was z22 min. Similar Vpu activity was observed in CD41
T cell lines and HeLa cells co-infected with VV-Vpu and
vCB-3 (not shown). In the absence of Vpu, CD4 exhibited
a t1/2 z4 h which is consistent with previously reported
half-lives of CD4 in human cell lines (39, 46). Therefore,
rVV-expressed Vpu has biological activity comparable to
Vpu expressed in human cell lines transfected with vpu1
HIV-1 subgenomic expression vectors (38, 44, 46).
The effect of Vpu on MHC-I molecules endogenous to
HeLa cells was examined 2.5 h after infection with VV-
Vpu or VV-UDEL1 by radiolabeling cells for 10 min and
chasing for up to 8 h. Class I molecules were collected
from detergent lysates using either the mAb W6/32 spe-
cific for conformed class I molecules (Fig. 4 A), an antiserum
specific for human b2m (Fig. 4 B), or the mAb SK81075
specific for nonconformed human H chains (Fig. 4 C). Ly-
sates were equalized to contain a comparable amount of in-
corporated [35S]methionine. To control for possible differ-
ences between the infectivity of virus stocks, cell lysates
were also subjected to immunocollection using a mixture
consisting of polyclonal antibodies specific for Vpu and the
mAb TW2.3 specific for vaccinia proteins E3L/E3L* (53;
Fig. 4 D). Relative amounts of H chain and E3L proteins
collected were quantitated by PhosphorImager analysis
(Fig. 4, histograms). Expression of Vpu dramatically reduced
the amount of class I H chains recovered with each of the
Figure 3. (A) Expression of
Vpu by recombinant vaccinia vi-
ruses. HeLa cells were infected
with rVVs expressing either
wild-type Vpu (VV-Vpu) or the
mutant VpuDEL1 (VV-UDEL1). 3 h
after infection, HeLa cells were
pulse labeled with [35S]methion-
ine for 25 min and cells express-
ing wild-type Vpu were chased
for up to 3 h. Cell lysates were
immunoprecipitated with anti-
Vpu sera (sheep and rabbit), sep-
arated in a 12.5% acryl aide gel,
and analyzed by fluorography.
Positions of 14C-labeled molecu-
lar weight marker proteins are
indicated on the left (M). (B)
Mouse L929 cells were co-
infected with rVVs expressing ei-
ther human CD4 (vCB-3) or wild-type Vpu (VV-Vpu). 3 h after infection, cells were pulse labeled with [35S]methionine for 7 min and chased for up to
4 h. CD4 molecules were recovered with anti-CD4 serum, separated in a 10% acryl aide gel, and analyzed by fluorography. Only a part of the fluoro-
gram demonstrating CD4-specific bands in the range of 55 kD is shown. Stability of CD4 present at different times during the chase period were calcu-
lated relative to the levels of CD4 present at the end of the pulse labeling (0), which was empirically defined as 100%.
Figure 4. Vpu induces loss of MHC-I H chains in HeLa cells. Parallel
cultures of HeLa cells were infected with rVVs VV-Vpu (1Vpu) or VV-
UDEL1 (2Vpu), and 2.5 h after infection cells were pulse labeled with
[35S]methionine for 10 min and chased for up to 8 h. Aliquots of cell ly-
sates were immunoprecipitated with mAb W6/32 (A), polyclonal anti-
bodies specific for human b2m (B), and mAb SK81075 specific for human
H chains (C), separated in a 10% acryl aide gel, and analyzed by fluorogra-
phy. Only bands corresponding to H chains in the range of 43 kD are
demonstrated in the upper part; the quantitation of H chains by means of
a PhosphorImager is demonstrated in the lower part. (D) Cell lysates were
immunoprecipitated with antibodies specific for Vpu and the mAb TW2.3
specific for vaccinia structural proteins E3L and E3L*. Proteins were sepa-
rated in a 12.5% acryl aide gel. Parts of the fluorogram depicting a range
between 14 and 30 kD are shown in the upper part; the quantitation of
the VV E3L is shown in the lower part.1300 HIV-1 Vpu Interferes with MHC Class I Biosynthesis
antibody preparations used at each of the time points tested
(Fig. 4, A–C). This cannot be trivially attributed to differ-
ences between the infectivity of VV-Vpu and VV-UDEL1,
as shown by the nearly identical amounts of VV proteins
E3L/E3L* recovered by mAb TW2.3 from each of the
time points (Fig. 4 D). Consistent with our previous find-
ing that Vpu does not affect the stability of the transferrin
receptor (CD72) in HIV-1–infected macrophages (33),
similar amounts of CD72 were recovered from VV-Vpu–
and VV-UDEL1–infected cells pulse radiolabeled for 10 min
with [35S]methionine and chased for up to 8 h (not shown).
Effects of rVV-expressed Vpu on rVV-expressed Class I Bio-
genesis. Notably, the effects of Vpu in class I biogenesis
were evident immediately upon pulse labeling, indicating
that Vpu affects early events in the assembly of class I mole-
cules. To facilitate biochemical evaluation of Vpu effects on
H chain synthesis, we examined the biosynthesis of mouse Kd
class I H chain expressed in HeLa cells co-infected with
VV-Kd, VV-UDEL1, or VV-Vpu (Fig. 5). The relatively
high levels of Kd expression allowed for shorter labeling
times with [35S]methionine. Cells were radiolabeled for 4
min, and immediately placed on ice to stop cellular metab-
olism. Cells were then either maintained on ice or incu-
bated for up to 2 h at 378C. Cell lysates were equalized for
[35S]methionine incorporation, and class I molecules were
collected with either mAb 215 specific for conformed Kd
(Fig. 5 A, mAB 215; reference 54) or with rabbit serum
specific for exon 8 (Fig. 5 B, pAb-ex8) that reacts with
Figure 5. Vpu disturbs an early process in MHC-I biogenesis. Parallel
cultures of HeLa cells were co-infected with VV-Kd expressing mouse H
chain Kd together with VV-Vpu (1Vpu), VV-UDEL1 (2Vpu), or VV-
ICP47 (1ICP47). 2.5 h after infection cells were pulse labeled with
[35S]methionine for 4 min, aliquoted in ice-cold medium, and chased at
378C for up to 2 h. Half of the cell lysates were immunoprecipitated with
mAb 215 (A) or with anti-Kd serum pAb-ex8 (B). Two rounds of immu-
nocollection were conducted and H chain molecules collected were ana-
lyzed by SDS-PAGE followed by fluorography. Only bands correspond-
ing to H chains are demonstrated in the upper part; the quantitation of H
chains detected after sequential collection (1st and 2nd) by means of a
PhosphorImager is demonstrated in the lower part, left histograms. Stabil-
ity of H chains recovered is demonstrated in the right histograms. Arrows
indicate mature glycosylated H chains detected after 2 h of chase period.
Figure 6. Transport of class I H chains is not affected by Vpu. Parallel
cultures of HeLa cells were co-infected with VV-Kd together with VV-
Vpu (Kd1Vpu) or VV-UDEL1 (Kd2Vpu), or VV-Kd alone (Kd). 2.5 h after
infection, cells were pulse labeled with [35S]methionine for 15 min and
chased for up to 8 h. Class I molecules were immunocollected with a 1:1
mixture of mAb 215 and anti-Kd serum pAb-ex8. Bead-bound material
was split and either not treated (2) or treated with endo H (1). Samples
were analyzed on a 8% acryl aide gel. Parts of the fluorograms depicting
H chain molecules are shown in A. The four bands in the treated samples
represent H chains partially or completely resistant (1CHO) or sensitive
(2CHO) to endo H treatment. Relative amounts of H chains seen in A
were quantitated and the quotient 1CHO/2CHO was calculated and
plotted against the time of the chase period (B).1301 Kerkau et al.
both folded and unfolded Kd molecules (54). To ensure
complete recovery of H chains, supernatants from the first
round of immunocollection were subjected to a second
round of precipitation with the same Ab (Fig. 5, A and B,
1st and 2nd). The relative amounts of H chains recovered af-
ter sequential collection were determined by PhosphorIm-
ager analysis (Fig. 5, A and B, left histograms). In the absence
of Vpu, the amount of Kd recovered by mAb 215 doubled
over the first 20 min of chase, and then decayed slowly.
This z10 min half-life of Kd folding is consistent with pre-
vious findings regarding class I folding (3). We also de-
tected a similar, but less marked, increase in Kd class I mol-
ecules collected by pAb-ex8. The increase in this case may
be due to initial masking of exon 8 by interaction with mo-
lecular chaperones (60). We observed a number of remark-
able effects of Vpu on Kd biogenesis. First, approximately
two- to threefold less Kd reactive with either mAb 215 or
pAb-ex8 was recovered from the unchased samples. Sec-
ond, instead of an initial increase, the amount of Kd recov-
ered precipitously declined over the first 20 min of chase
period. Vpu had no significant effect on the stability of Kd
that survived the initial effect, which are transported through
the Golgi complex with kinetics similar to Kd synthesized
in the control infected cells, as indicated by the recovery of
a Kd form with lower mobility on SDS-PAGE (indicated
by arrows in Fig. 5, A and B) that probably represents Kd
with terminally sialyated N-linked oligosaccharides.
The fate of Kd that escaped the early action of Vpu was
further examined in an experiment in which Kd H chains,
collected from detergent lysates with a mixture of mAb 215
and pAb-ex8, was digested with endo H (Fig. 6). Kd pos-
sesses three N-linked oligosaccharides. Endo H removes
high mannose N-linked oligosaccharides, but not N-linked
oligosaccharides that have been acted on by Golgi man-
nosidase II. The rate of H chain transport to the mannosi-
dase II–containing compartment was determined by calcu-
lating the ratio of H chain partially or completely resistant
to endo H digestion (Fig. 6 A, 1CHO) to endo H–sensi-
tive H chains (Fig. 6 A, 2CHO). Vpu expression had no
significant effect on the kinetics of acquisition of endo H
resistance (Fig. 6 B). This confirms that Kd molecules that
escape the early destructive effect by Vpu in the ER are ex-
ported and processed in a manner indistinguishable from H
chains produced in cells not expressing Vpu.
Effects of rVV-expressed Vpu on Class I Cell-Surface Expres-
sion. The effects of Vpu on endogenous class I molecules
present on the cell surface were investigated by testing
rVV-infected HeLa cells for expression of conformed HLA
molecules using either the mAb W6/32 or anti-b2m anti-
bodies directly conjugated to FITC (Fig. 7, A and B). In-
fection with rVV resulted in a 20–30% decrease in binding
of either antibody, probably due to ongoing turnover of
class I molecules combined with reduced replacement due
to VV suppression on host cell protein synthesis. Staining
was reduced a further 5–10% by Vpu, which is likely due
to inhibition of expression of the reduced amounts of class
I molecules produced in the face of the ongoing VV infec-
tion. This latter effect is selective for class I molecules since
VV-Vpu and VV-UDEL1 infections reduced surface levels of
endogenous CD72 nearly identically (Fig. 7 C), the reduc-
tion again probably related to VV induced suppression of
host protein synthesis. Furthermore, Vpu had no effect on
cell surface expression of mouse ICAM-1 (CD54) in HeLa
cells co-infected with VV-Vpu and VV-ICAM (Fig. 7 D).
In contrast, Vpu reduced cell-surface expression of Kb class
I molecules co-synthesized in HeLa cells infected with VV-
Vpu and VV-Kb (Fig. 7 E). These findings further demon-
strate that Vpu selectively inhibits the cell surface expres-
sion of newly synthesized class I molecules, but has no or
very minor effects on preexisting cell surface class I mole-
cules.
Comparison of Vpu to HSV ICP47. Given the effect of
Vpu on early events in class I biogenesis, it was of interest
to compare the effects of Vpu with the ICP47 protein of
HSV. ICP47 is a competitive inhibitor of TAP that greatly
reduces the supply of class I–binding peptides (16–18, 61,
62). In several of the experiments described above, we in-
cluded an additional sample in which VV-ICP47 was sub-
stituted for VV-Vpu. In the pulse chase experiments (Fig.
5, A and B, 1ICP47), the effects of ICP47 and Vpu were
quite disparate; In contrast to Vpu, ICP47 did not cause an
immediate reduction in the amount of H chains recovered
Figure 7. Vpu downregulates cell surface expression of MHC-I molecules. HeLa cells were infected with rVVs expressing either wild-type Vpu
(1Vpu), the vpu mutant VpuDEL1 (2Vpu), or the HSV protein ICP47 (1ICP47). In D and C cells were co-infected with rVV expressing the mouse gly-
coprotein ICAM-1 (CD54); in E cells were co-infected with rVV expressing mouse H chain Kb. Cells were stained 5 h after infection with antibodies
specific for human b2m (A), human MHC-I (mAb W6/32; B), human transferin receptor (TFR; CD72; C), mouse H chain Kb (E), or mouse ICAM-1 (D).1302 HIV-1 Vpu Interferes with MHC Class I Biosynthesis
at the end of the pulse-labeling time. In fact, the amount of
H chains precipitated with the conformation-sensitive mAb
215 increased slightly over the first 10 min of chase period
(Fig. 5 A, 1ICP47). Consistent with previous findings
(16–18, 61, 62), ICP47 expression results in the recovery of
less conformed and total Kd over the chase period. Notably,
the initial loss of immunoreactive class I induced by ICP47
occurs with a half-life approximately twice as long as the
Vpu-induced loss (Fig. 5, A and B). Another important dif-
ference is that ICP47 delays the transport of class I mole-
cules from the ER, as demonstrated by the failure of class I
molecules to demonstrate the decrease in mobility associ-
ated with siaylation (Fig. 5, A and B, 1ICP47). ICP47 and
Vpu have a similar effect on class I surface expression (Fig.
7 E), blocking expression of VV-encoded Kb to the same
extent as Vpu, while, like Vpu, having little effect on pre-
existing surface HLA moleclues (Fig. 7, A and B).
Discussion
As with many viruses, HIV-1 induces a rapid TCD81 re-
sponse in the host (63, 64). However, unlike most viruses,
HIV-1 is not eradicated completely and continues to repli-
cate for many years during the asymptomatic period of in-
fection before the onset of AIDS. During this latent period,
HIV-specific TCD81 are active and present in PBL at very
high levels relative to other viral infections (constituting up
to 1% of circulating TCD81; reference 65), only gradually
declining in parallel with TCD41 during the progression to
AIDS. The presence of a vigorous TCD81 response raises
the question of how the virus can persist in the face of an
immune effector mechanism that is usually highly effective
at eradicating virus. One possibility is that a subset of virus-
producing cells are resistant to TCD81-mediated anti-viral
effects.
Several mechanisms, including antigenic drift (63, 66,
67, 68), exhaustion of TCD81 response by high level of anti-
gen exposure (69), or deficiencies in HIV-1 antigen pro-
cessing and presentation (11, 19–21, 57) have been pro-
posed for resistance to TCD81-mediated lysis. In the present
paper, we show that Vpu interferes with the expression of
MHC-I molecules on the surface of HIV-1–infected cells.
Indeed, viruses lacking Vpu demonstrate only a minor de-
crease in class I expression. It seems, therefore, that the
Tat-mediated decrease in class I transcripts (11) plays little
role (23) in the decrease in class I expression. Rather, we
conclude that Vpu is required for most of the inhibition of
cell surface MHC-I expression seen in HIV-infected cells,
and propose that this may contribute to the inability of
HIV-specific TCD81 to eradicate the virus in infected indi-
viduals.
When expressed in the context of HIV-1 infection, we
observed two effects of Vpu on class I molecules: (a) de-
creased recovery of class I H chains collected with immature
N-linked oligosaccharides immediately after [35S]methio-
nine labeling and (b) decreased stability of class I molecules
with mature N-linked oligosaccharides. Only the former
effect was observed using rVV to express Vpu. There are
several explanations for this discrepancy. First, Vpu may act
in concert with other viral gene products to affect the sta-
bility of class I molecules expressed on the cell surface. In
this regard, it was recently reported that the HIV Nef gene
product induces the degradation of cell surface class I mole-
cules (57). Possibly, the activity of Nef and/or Vpu is in-
creased by coexpression of both proteins. Second, alter-
ations in cellular metabolism induced by rVV infection
may interfere with the ability of Vpu to affect cell surface
class I molecules. Third, Vpu is known to augment by two
to threefold virus release from PBL (33). Since in HIV-1
particles, class I molecules constitute up to z20% of the
concentration of Gag protein on a molar basis (58), it is
likely that at least some of Vpu-dependent loss in class I
molecules with mature N-linked oligosaccharides is due to
increased virion production with its attendant increase in
class I shedding.
When expressed by rVV, Vpu reduced the amount of
class I molecules recovered after brief labeling with [35S]meth-
ionine, and, during a 20-min chase period, Vpu also de-
creased the metabolic stability of the H chains with imma-
ture N-linked oligosaccharides that escaped the immediate
effects of Vpu. We interpret the latter phenomenon to rep-
resent the continuation of the same process resulting in de-
creased recovery of pulse-labeled heavy chains. Impor-
tantly, the effect of Vpu on class I molecules was clearly
distinguished from that of ICP47 which acts by blocking
the peptide transporting activity of TAP. This indicates that
the effects of Vpu on class I biogenesis do not result from a
decrease in the quantity or quality of peptides available for
class I binding. We have not formally demonstrated that
Vpu induces the degradation of MHC-I molecules. It is
also possible that the decreased recovery of class I molecules
is due to Vpu-induced decreases in solubility of class I mol-
ecules in the detergents used for extraction, or to the asso-
ciation with proteins that block antibody accessibility to
class I molecules.
How might Vpu compromise biogenesis of class I mole-
cules? It was recently demonstrated (46) that the two previ-
ously defined biological functions of Vpu, CD4 degrada-
tion and regulation of virus release, are controlled by two
separable structural and functional domains. CD4 degrada-
tion requires phosphorylation of the Vpu cytoplasmic tail
(44) and the binding of Vpu to CD4 (70) trapped in the
ER by complex formation with the HIV-1 envelope pre-
cursor gp160 (40). In contrast, the effect of Vpu on virus
particle release is regulated by an ion channel activity of its
transmembrane domain (71, 72), occurs in a post-ER com-
partment (44), and does not require phosphorylation of
Vpu (44). Vpu, therefore, possesses at least two distinct ac-
tivities: first, alteration of the ionic milieu in a post-ER
compartment, and second, targeting of proteins located in
the ER for destruction. Our proposal that Vpu induces a
rapid decay of nascent class I H chains is more consistent
with the known ER activity of Vpu, and, based on the
ability of Vpu to induce proteolysis of nascent CD4 in the
ER (38, 39), it is likely that Vpu acts similarly on MHC
class I molecules.1303 Kerkau et al.
It was recently demonstrated that the US2 and US11 gene
products of human cytomegalovirus are able to induce the
rapid degradation of class I H chains (15, 73). Both act by
routing newly synthesized class I molecules to the cytosol,
where degradation requires the activity of proteasomes, in
as much as it was blocked by proteasome inhibitors (15).
The interaction of H chains with one of the components of
the translocon suggest that US11 directs H chains in a ret-
rograde fashion through the sec61-containing pore used to
insert proteins into the ER (73). Indeed, based on this and
other recent findings in Saccharomyces cerevisae (74), it seems
likely that many cases of presumed degradation of mem-
brane proteins by ER proteases are, in fact, due to routing
of proteins to the cytosol where they are degraded in a pro-
cess requiring active proteasomes. It is necessary to reexam-
ine if the Vpu-induced CD4 degradation involves the ubi-
quitin-proteasome pathway and whether a similar process is
used for class I molecules. It will also be of great interest to
determine the shared features of class I H chains and CD4
that target them for Vpu-induced destruction while other
glycoproteins such as Env, CD8 (75), CD54, and CD72
are spared.
In summary, our data indicate that Vpu is the major fac-
tor in the reduction of MHC class I molecules on HIV-1
infected cells. This adds another function to the two previ-
ously ascribed to Vpu, CD4 degradation and virus release.
It is possible that one or more of these functions is an unin-
tended byproduct of the other(s). However, it is equally
plausible that each contributes to the evolutionary fitness of
the virus. The relative contributions of these effects may
vary depending on the nature of other viral genes or the host
response to the virus. It will be a challenge to determine
the biological significance of these three functions of Vpu.
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